Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use.

Unlabelled: OBJECTIVE; To evaluate the results of a large cohort of non-responder or relapsing responder patients with chronic hepatitis C retreated with various schedules of interferon (IFN).

Methods: Our study included 276 patients (158 non-responders and 118 relapsing responders) who underwent IFN retreatments. Among the non-responder group, 158 patients underwent further courses of IFN.

[Bacterial infections in HIV patients].

Aim Of The Study And Methods: Retrospective analysis of bacterial infections occurring in 400 admissions of HIV-positive patients in the Infectious Diseases Unit of the Azienda Ospedale Santa Corona, Pietra Ligure (SV), from January 1994 to September 1996.

Results: 56 episodes were documented (14% of admissions): 24 (43%) hospital acquired (11 sepsis, 5 pneumonias, 6 urinary-tract infections, 1 infection of a prosthetic device) and 32 (57%) community-acquired (9 sepsis, 13 pneumonias [6 with bacteremia] 9 urinary-tract infections, 1 endocarditis). At time of diagnosis mean absolute CD4-lymphocyte count was 106/cmm (95% Cl 62-150) and mean neutrophil count was 4.

Dorfman-Chanarin syndrome: a case with prevalent hepatic involvement.

Background/aims: Dorfman-Chanarin syndrome is a very rare condition determined by an autosomal recessive inherited disorder of neutral lipid metabolism. The syndrome is defined by the association of ichthyosiform nonbullous erythroderma, vacuoles in the leukocytes and variable involvement of liver, muscle and central nervous system. Only 19 cases have been described worldwide.

Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?

Soluble HLA class I antigens (sHLA-I), beta 2-microglobulin (beta 2-mu) and alanine aminotransferase (ALT) serum levels have been evaluated in 16 patients affected by chronic hepatitis C treated for six months with recombinant interferon-alpha (rIFN-alpha, 3 MU three times a week). The predictor role of sHLA-I and ALT modifications with respect to the response to rIFN-alpha therapy was also evaluated. Six patients responded (group 1), five patients relapsed followed in initial responses (group 2), and five did not respond to rIFN-alpha treatment (group 3).

Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses.

Sixty patients of both sexes with biopsy-proven chronic hepatitis C were randomized to receive lymphoblastoid interferon 3 MU or 6 MU three times weekly for 6 months. A follow-up period of 3 months at the end of the therapy was scheduled. Thirty-two patients (53.